Abstract
Background: Amyloid beta (Aβ) accumulates in the human brain in an age-dependent manner during normal aging. However, Aβ accumulation has not been observed in rodents during normal aging. Tree shrews, the experimental animals studied here, are as small as rats but have a longer life span than rodents.
Methods: We investigated Aβ accumulations in the brains of young and aged tree shrews by amyloid histochemistry and immunohistochemistry using antibodies to Aβ-42, Aβ-40, Aβ-16 and amyloid precursor protein (APP).
Results: In the brain of young tree shrews, there were no Aβ- immunoreactive (-ir) and APP-ir profiles. In the brains of aged tree shrews, Aβ-42-ir neuronal profiles were observed in the cortex, subiculum, basal ganglia, mammillary body and hypothalamus, but there were only a few weak Congo red-positive amyloid deposits. Aβ-42-, Aβ-40-, Aβ-16- and APP-ir blood vessels were observed.
Conclusions: An early stage of amyloid accumulation occurs in the brains of aged tree shrews, indicating that this animal may be a good model for studying the start of Aβ accumulation.
Keywords: Normal aging, blood vessel, amyloid deposit, Congo red, Alzheimer’s disease, Tupai belangeri.
Current Aging Science
Title: Amyloid Beta (Aβ) Protein- and Amyloid Precursor Protein (APP)- Immunoreactive Structures in the Brains of Aged Tree Shrews
Volume: 3 Issue: 3
Author(s): Akiko Yamashita, Eberhard Fuchs, Masato Taira and Motoharu Hayashi
Affiliation:
Keywords: Normal aging, blood vessel, amyloid deposit, Congo red, Alzheimer’s disease, Tupai belangeri.
Abstract: Background: Amyloid beta (Aβ) accumulates in the human brain in an age-dependent manner during normal aging. However, Aβ accumulation has not been observed in rodents during normal aging. Tree shrews, the experimental animals studied here, are as small as rats but have a longer life span than rodents.
Methods: We investigated Aβ accumulations in the brains of young and aged tree shrews by amyloid histochemistry and immunohistochemistry using antibodies to Aβ-42, Aβ-40, Aβ-16 and amyloid precursor protein (APP).
Results: In the brain of young tree shrews, there were no Aβ- immunoreactive (-ir) and APP-ir profiles. In the brains of aged tree shrews, Aβ-42-ir neuronal profiles were observed in the cortex, subiculum, basal ganglia, mammillary body and hypothalamus, but there were only a few weak Congo red-positive amyloid deposits. Aβ-42-, Aβ-40-, Aβ-16- and APP-ir blood vessels were observed.
Conclusions: An early stage of amyloid accumulation occurs in the brains of aged tree shrews, indicating that this animal may be a good model for studying the start of Aβ accumulation.
Export Options
About this article
Cite this article as:
Yamashita Akiko, Fuchs Eberhard, Taira Masato and Hayashi Motoharu, Amyloid Beta (Aβ) Protein- and Amyloid Precursor Protein (APP)- Immunoreactive Structures in the Brains of Aged Tree Shrews, Current Aging Science 2010; 3 (3) . https://dx.doi.org/10.2174/1874609811003030230
DOI https://dx.doi.org/10.2174/1874609811003030230 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System
Current Neuropharmacology Subject Index to Volume 4
Current Molecular Medicine TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Cytosine Methyltransferases as Tumor Markers
Current Genomics Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry The Crosstalk between Tissue Engineering and Pharmaceutical Biotechnology: Recent Advances and Future Directions
Current Pharmaceutical Biotechnology Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by “ Molecular Tweezers” - from the Test Tube to Animal Models
Current Pharmaceutical Design G-Protein Coupled Receptors (GPCRs): A Comprehensive Computational Perspective
Combinatorial Chemistry & High Throughput Screening Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment
Current Drug Delivery Procyanidin B2 3,3″-di-O-gallate Inhibits Endothelial Cells Growth and Motility by Targeting VEGFR2 and Integrin Signaling Pathways
Current Cancer Drug Targets Decreasing Systemic Toxicity Via Transdermal Delivery of Anticancer Drugs
Current Drug Metabolism Opportunities to Improve the Prevention and Treatment of Cervical Cancer
Current Molecular Medicine Targeting the Mitochondrial Electron Transport Chain Complexes for the Induction of Apoptosis and Cancer Treatment
Current Pharmaceutical Biotechnology Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design